# Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

> **NCT01251835** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Sitaxsentan alone
- **DRUG:** Sitaxsentan
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT01251835
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251835, "Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01251835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*